RT Journal Article
SR Electronic
T1 Ivabradine Treatment to Prevent Anthracycline-Induced Cardiotoxicity: A Randomized Clinical Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.30.24316463
DO 10.1101/2024.10.30.24316463
A1 Rizk, Stephanie Itala
A1 Costa, Isabela Bispo Santos da Silva
A1 Cruz, Cecilia Beatriz Bittencourt Viana
A1 Pileggi, Brunna
A1 Andrade, Fernanda Thereza de Almeida
A1 Gonzalez, Thalita Barbosa
A1 Bittar, Cristina Salvadori
A1 Fukushima, Julia Tizue
A1 Quintao, Vinicius Caldeira
A1 Osawa, Eduardo Atsushi
A1 Alves, Juliana Barbosa Sobral
A1 Fonseca, Silvia Moulin Ribeiro
A1 Garcia, Diego Ribeiro
A1 Pereira, Juliana
A1 Buccheri, Valeria
A1 Ávila, Juliana
A1 Kawahara, Lucas Tokio
A1 Barros, Cecilia Chie Sakaguchi
A1 Ikeoka, Lucas Takeshi
A1 Nakada, Letícia Naomi
A1 Fellini, Mariella
A1 Rocha, Vanderson Geraldo
A1 Rego, Eduardo Magalhães
A1 Hoff, Paulo Marcelo Gehm
A1 Kalil Filho, Roberto
A1 Landoni, Giovanni
A1 Hajjar, Ludhmila Abrahão
YR 2024
UL http://medrxiv.org/content/early/2024/11/05/2024.10.30.24316463.abstract
AB Background Cancer therapy-related cardiac dysfunction frequently occurs in patients receiving anthracycline. Ivabradine reduces the heart rate without affecting contractility and has shown anti-inflammatory, antioxidant, and antiapoptotic effects in experimental models of cardiotoxicity. This study aims to evaluate the effect of ivabradine on cancer therapy-related cardiac dysfunction incidence in patients with lymphoma or sarcoma treated with anthracycline.Methods This study was a prospective, randomized, and triple-blind trial. Patients starting anthracycline therapy were given either ivabradine 5 mg twice daily or placebo until 30 days after completing treatment. The primary outcome was a ≥10% relative reduction in global longitudinal strain at 12 months. The secondary outcomes included 12-month clinical outcomes, a ≥10% decrease in the left ventricular ejection fraction to <55%, diastolic dysfunction, and troponin T and NT-proBNP levels.Results This study was conducted with 107 patients (51 in the ivabradine group and 56 in the placebo group). The median dose of anthracycline was 300 mg/m2 (250--300 mg/m2) in both groups. A ≥10% relative reduction in global longitudinal strain at 12 months was reached in 57% of the ivabradine group and in 50% of the placebo group (OR 1.32, 95% CI: -0.612.83, p=.477). Fewer patients in the ivabradine group than in the placebo group had troponin T levels ≥14 ng/L [16 (39.0%) vs. 23 (62.2%), p=0.041] at 6 months. There were no differences in the other secondary outcomes.Conclusions A fixed 10 mg/day dose of ivabradine does not protect cancer patients against anthracycline cardiotoxicity.Clinical trials registration NCT03650205 https://clinicaltrials.gov/study/NCT03650205?cond=NCT03650205&rank=1Clinical perspectivesThis study found that ivabradine at a fixed dose of 10 mg/day does not effectively prevent cardiotoxicity in cancer patients undergoing anthracycline (ANT) therapy, contrary to previous expectations.These findings suggest that ivabradine may not be sufficient as a cardioprotective agent in ANT therapy, emphasizing the need to explore additional or alternative strategies to manage cardiotoxicity in cancer patients.The study highlights a potentially complex interaction between ANT and cardiac tissue, indicating a need for further research to fully understand and address this risk.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03650205 https://clinicaltrials.gov/study/NCT03650205?cond=NCT03650205&rank=1Funding StatementThis trial received external funding from The Sao Paulo Research Foundation (FAPESP) under the registry 2015/22814-5.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IPAC trial was a triple-blind, randomized, placebo-controlled study conducted at the Instituto do Câncer do Estado de São Paulo (ICESP) and at the Instituto do Coração (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil, after approval by the Comissäo de Ética do Hospital das Clínicas da FMUSP (Capepesq) (Research Ethics Committee).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.Non-standard abbreviations and acronymsANTanthracyclineCTRCDcancer therapy-related cardiac dysfunctionEKGelectrocardiogramHFheart failureHRheart rateLVleft ventricleLVEFleft ventricular ejection fractionNT-proBNPN-terminal pro B-type natriuretic peptideTTEtransthoracic echocardiogramGLSglobal longitudinal strain